TY - JOUR
T1 - Low serum insulin-like growth factor 1 (IGF-1)
T2 - A significant association with prostate cancer
AU - Baffa, R.
AU - Reiss, K.
AU - El-Gabry, E. A.
AU - Sedor, J.
AU - Moy, M. L.
AU - Shupp-Byrne, D.
AU - Strup, S. E.
AU - Hauck, W. W.
AU - Baserga, R.
AU - Gomella, L. G.
PY - 2000
Y1 - 2000
N2 - Purpose: Insulin-like growth factor 1 (IGF-1) is an important mitogenic and antiapoptotic peptide that affects the proliferation of normal and malignant cells. Contradictory reports on the association between serum IGF-1 level and prostate cancer have been highlighted in the recent literature. The purpose of this study was to investigate the relation between serum levels of IGF-1 and prostate cancer. Materials and Methods: We analyzed a population of 57 patients who underwent radical prostatectomy (RP) for adenocarcinoma. Serum samples were collected before RP (TO), 6 months after RP (T6), and from 39 age-matched controls. IGF- 1 levels were determined by the active IGF-1 Elisa kit (Diagnostic Systems Laboratories, Inc.). Parallel samples were evaluated for prostate-specific antigen (PSA) levels. Data between groups were analyzed using Welch's t-test and levels before RP and after 6 months were compared by paired t-test. Results: The normal mean serum IGF-1 for case patients at TO (124.6 ± 58.2 ng/mL) was significantly lower than the control subjects (157.5 ± 70.8 ng/mL; p = .0192). The normal mean serum IGF-1 for case patients at TO (124.91 ± 58.6 ng/mL) also was significantly lower when it was compared with the T6 group (148.49 ± 57.2 ng/mL; p = .0056). No association was found between IGF-1 and PSA blood levels, or IGF-1 and patient weight (p = 0.2434). An inverse relation between IGF-1 levels and age in the normal controls (p = .0041) was observed. Conclusion: Findings of this study indicate a significant association between low serum levels of IGF-1 and prostate cancer.
AB - Purpose: Insulin-like growth factor 1 (IGF-1) is an important mitogenic and antiapoptotic peptide that affects the proliferation of normal and malignant cells. Contradictory reports on the association between serum IGF-1 level and prostate cancer have been highlighted in the recent literature. The purpose of this study was to investigate the relation between serum levels of IGF-1 and prostate cancer. Materials and Methods: We analyzed a population of 57 patients who underwent radical prostatectomy (RP) for adenocarcinoma. Serum samples were collected before RP (TO), 6 months after RP (T6), and from 39 age-matched controls. IGF- 1 levels were determined by the active IGF-1 Elisa kit (Diagnostic Systems Laboratories, Inc.). Parallel samples were evaluated for prostate-specific antigen (PSA) levels. Data between groups were analyzed using Welch's t-test and levels before RP and after 6 months were compared by paired t-test. Results: The normal mean serum IGF-1 for case patients at TO (124.6 ± 58.2 ng/mL) was significantly lower than the control subjects (157.5 ± 70.8 ng/mL; p = .0192). The normal mean serum IGF-1 for case patients at TO (124.91 ± 58.6 ng/mL) also was significantly lower when it was compared with the T6 group (148.49 ± 57.2 ng/mL; p = .0056). No association was found between IGF-1 and PSA blood levels, or IGF-1 and patient weight (p = 0.2434). An inverse relation between IGF-1 levels and age in the normal controls (p = .0041) was observed. Conclusion: Findings of this study indicate a significant association between low serum levels of IGF-1 and prostate cancer.
KW - Insulin-like growth factor 1
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=0033871095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033871095&partnerID=8YFLogxK
M3 - Article
C2 - 10963500
AN - SCOPUS:0033871095
SN - 1079-3259
VL - 6
SP - 236
EP - 239
JO - Techniques in Urology
JF - Techniques in Urology
IS - 3
ER -
